Affymax and Takeda report positive Phase II data for anemia drug
Preliminary data from the trial showed that Hematide administered once every four weeks was well tolerated and maintained mean hemoglobin levels between 11 and 12g/dL in patients with
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.